[The evaluation of the influence of growth hormone therapy on growing process and metabolic functions in patients after treatment of craniopharyngioma].
BACKGROUND
Craniopharyngioma (CP) is a tumor, which damages pituitary function because of its localization. Panhypopituitarism (PHP) and excessive weight gain with lipid dysfunction are frequently observed. The growth hormone therapy (rGH) profits in the increase of growth rate and also may have metabolic effects like body weight reduction.


OBJECTIVE
The evaluation of benefits from rGH therapy in patients cured from CP.


METHODS
12 patients (7 boys and 5 girls) treated for CP with surgery; 3 of them also underwent radiotherapy. The mean age at examination time was 11.7 yrs; remission time 2.96 yrs; rGH therapy started on average 3.69 yrs after the surgery. Height (hSDS), weight, BMI were measured after the surgery, before and after 1 yr of rGH treatment. Height velocity (HV) was evaluated before and after 1 yr of rGH therapy. Pituitary GH-function was assessed. In addition, measurements of TSH, ACTH, LH, FSH. Cholesterol, LDL, HDL, triglycerides and HbA1c were estimated before and after one year of rGH therapy.


RESULTS
All patients presented PHP. The GH-peak average 1.53 mIU/l; IGF-1 39.37 ng/ml; TSH 0.1 U/l; ACTH 17.48 pg/ml; LH 0.13 U/l; FSH 0.41 mIU/ml. HSDS after oncological treatment (OT) average -1.66 SD and decreased significantly until rGH therapy; weight after OT average 28.45 kg and until rGH therapy increased significantly; BMI after OT average 19.26 and increased significantly until rGH therapy as well. HV was on average 3.34 cm/yr until rGH started. After one year of rGH therapy hSDS and HV increased significantly; they average -1.65SD and 10.21 cm/yr respectively. BMI, HbA1c and LDL decreased significantly. During rGH therapy neither tumor recurrence nor severe side effects were observed.


CONCLUSIONS
rGH therapy of patients cured from CP influences profitably not only growth rate, but also BMI reduction and the decrease in cholesterol LDL and HbA1c.
Okońska
Maja
M
Klinika Pediatrii, Uniwersyteckie Centrum Kliniczne, Gdansk. majkul@wp.pl
Birkholz
Dorota
D
Korpal-Szczyrska
Maria
M
Adamkiewicz-Drozyńska
Elzbieta
E
Alska
Anna
A
Magnuszewska
Hanna
H
D002648:Child; D003397:Craniopharyngioma / Q000150:complications* / Q000378:metabolism / Q000532:radiotherapy / Q000601:surgery; D005260:Female; D006130:Growth Disorders / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism; D019382:Human Growth Hormone / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D050177:Overweight / Q000188:drug therapy / Q000209:etiology; D010911:Pituitary Neoplasms / Q000150:complications* / Q000378:metabolism / Q000532:radiotherapy / Q000601:surgery; D011994:Recombinant Proteins
D011994:Recombinant Proteins; D019382:Human Growth Hormone